Molecular Oncology Department Metrics

View the grants and publications from the Department of Molecular Oncology.

Grants
  • Intrinsic Disorder Controls the Function 0f p53 and Other Cancer Associated IDPs
    Sponsor: Univ of South Florida
    PI (MPI):Chen, J.
  • CPTAC Phase III
    Sponsor: Nat Institutes of Health
    PI:Koomen, J.
  • Identification of Non-Coding RNAs to Therapeutically Target Undruggable Pathways in Metastatic Lung Adenocarcinma and Squamous Cell Carcinoma
    Sponsor: Nat Institutes of Health
    PI:Flores, E.
  • Ubiquitination-dependent Regulation of BRAF Function in Melanoma
    Sponsor: Amer Cancer Society
    PI:Wan, L.
  • Anti-tumor Potential of Temperature-Sensitive p53 Mutants
    Sponsor: Nat Institutes of Health
    PI (Contact):Chen, J.,PI (MPI):Mann, M.
  • Integrated Program in Cancer and Data Science
    Sponsor: Nat Institutes of Health
    PI (Contact):Cress, D.,PI (MPI):Flores, E.,PI (MPI):Fridley, B.
  • Targeting Heme Dependency in Leukemia
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Reuther, G.
  • Discovery of p53 inhibitors for reducing toxicity of chemotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Chen, J.
  • Proteogenomics of Metastatic Heterogeneity and Therapeutic Resistance in Lung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI (Contact):Koomen, J.,CO-PI:Boyle, T.
  • Identifying Metabolic Vulnerabilities in Lung Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Flores, E.,PI (MPI):Haura, E.,Project PI:DeNicola, G.,Project PI:Rodriguez, P.,Project PI:Cleveland, J.,Core PI/Director:Fridley, B.,Core PI/Director:Cress, D.,Core PI/Director:Koomen, J.
  • Direct Control of the human CMG Helicase by Myc and Rb
    Sponsor: Nat Institutes of Health
    PI:Alexandrow, M.
  • Exploring miR-29 in Melanoma Progression and Prevention
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms
    Sponsor: Nat Institutes of Health
    PI:Reuther, G.
  • Propionate metabolism as an essential metabolic adaptation for tumor progression
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Vitamin B12 supplementation as novel therapeutic strategy to improve cancer-associated outcomes
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Chromosome 1q ceRNAs in melanoma progression and metastasis
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • Molecular Drivers of Lung Cancer in Hispanics
    Sponsor: Nat Institutes of Health
    PI (Contact):Cress, D.,PI (MPI):Teer, J.
  • Aging as a selective pressure that drives tumor progression
    Sponsor: Nat Institutes of Health
    PI:Gomes, A.
  • Assessing the role of TROLLs as markers of response to chemotherapy in TNBCs
    Sponsor: APIS Assay Technologies - UK
    PI:Flores, E.
  • Elucidating PTEN tumor suppression in melanoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Karreth, F.
  • Biophysical basis for enzyme mediated deglycation in protein repair
    Sponsor: Nat Institutes of Health
    PI:Binning, J.
  • Characterizing oncogenic function of ITCH in melanoma
    Sponsor: Nat Institutes of Health
    PI:Wan, L.
  • Mechanisms of age-induced chemotherapeutic resistance in lung cancer
    Sponsor: Amer Lung Assoc
    PI:Gomes, A.
  • Characterization of the Oncogenic Potential of circRNAs in Melanoma
    Sponsor: Nat Institutes of Health
    PI:Karreth, F.
  • Elucidating the Oncogenic Role of sMAF Proteins in Melanoma
    Sponsor: Amer Cancer Society
    PI:Karreth, F.
  • Allosteric Regulation of MDMX by Protein Disorder
    Sponsor: Nat Institutes of Health
    PI (Contact):Chen, J.
  • Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
  • Dual Source Ion Mobility-Mass Spectrometer
    Sponsor: Nat Institutes of Health
    PI:Koomen, J.
  • NAD+: A Missing Link Between Aging and Pancreatic Tumorigenesis
    Sponsor: Phi Beta Psi
    PI:Gomes, A.
  • Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets
    Sponsor: Nat Institutes of Health
    PI:Kissil, J.
  • Establishing the functional differences between variant oncogenic KRAS alleles and identification of allele-selective inhibitors
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Kissil, J.
  • Pilot Study of Bladder Cancer Chemo Sensitization by Hypothermia
    Sponsor: Moffitt Cancer Center
    PI (Contact):Chen, J.,PI:Huang, J.,PI:Li, R.,PI:Spiess, P.
  • Deep Learning Module for annotation of murine lung metastases in digital pathology
    Sponsor: Moffitt Cancer Center
    PI (Contact):Flores, E.,PI:Stringfield, O.
  • Novel Mouse Models of Uveal Melanoma
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Karreth, F.
  • Exploring the Impact of HSP90 Inhibition on Antigen Presentation and Anti-Tumor Immune Responses
    Sponsor: Nat Institutes of Health
    PI:Jaeger, A.
  • Assessing novel therapeutics against RAS activation in models of myeloproliferative neoplasm and JAK2 inhibitor resistance
    Sponsor: Revolution Medicines Inc
    PI:Reuther, G.
  • Immunosuppressive mechanism of ITCH in the melanoma tumor microenvironment
    Sponsor: Moffitt Cancer Center
    PI:Wan, L.
Publications
  • Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
  • Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 Sep. Pubmedid: 36053203.
  • Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030.
  • Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-independent metabolic reprogramming precedes lymphoma-driven changes in T-cell fate. Cancer Immunol Res. 2022 Aug. Pubmedid: 35969234.
  • Madanayake TW, Welsh EA, Darville LNF, Koomen JM, Chalfant CE, Haura EB, Robinson TJ. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition. Nucleic Acid Ther. 2022 Jul. Pubmedid: 35861718.
  • Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35793871. Pmcid: PMC9260835.
  • Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan SL, Shalek AK, Spranger S, White FM, Jacks T. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022 Jul.607(7917):149-155. Pubmedid: 35705813.
  • Chitsazzadeh V, Nguyen TN, de Mingo Pulido A, Bittencourt BB, Du L, Adelmann CH, Rivera IO, Nguyen KA, Guerra LD, Davis A, Napoli M, Ma W, Davis RE, Rajapakshe K, Coarfa C, Flores ER, Tsai KY. miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFβR3. J Invest Dermatol. 2022 Jul.142(7):1956-1965.e2. Pubmedid: 34890627. Pmcid: PMC9174350.
  • Drapela S, Ilter D, Gomes AP. Metabolic reprogramming: a bridge between aging and tumorigenesis. Mol Oncol. 2022 Jun. Pubmedid: 35666002.
  • Avalon NE, Nafie J, De Marco Verissimo C, Warrensford LC, Dietrick SG, Pittman AR, Young RM, Kearns FL, Smalley T, Binning JM, Dalton JP, Johnson MP, Woodcock HL, Allcock AL, Baker BJ. Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral Duva florida, Displays Inhibition of the SARS-CoV-2 3CLpro Enzyme. J Nat Prod. 2022 May.85(5):1315-1323. Pubmedid: 35549259. Pmcid: PMC9127705.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Hongu T, Pein M, Insua-Rodríguez J, Gutjahr E, Mattavelli G, Meier J, Decker K, Descot A, Bozza M, Harbottle R, Trumpp A, Sinn HP, Riedel A, Oskarsson T. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nat Cancer. 2022 Apr.3(4):486-504. Pubmedid: 35469015. Pmcid: PMC9046090.
  • Riedel A, Helal M, Pedro L, Swietlik JJ, Shorthouse D, Schmitz W, Haas L, Young T, da Costa ASH, Davidson S, Bhandare P, Wolf E, Hall BA, Frezza C, Oskarsson T, Shields JD. Tumor-Derived Lactic Acid Modulates Activation and Metabolic Status of Draining Lymph Node Stroma. Cancer Immunol Res. 2022 Apr.10(4):482-497. Pubmedid: 35362044. Pmcid: PMC7612582.
  • Wang B, Wu HH, Abuetabh Y, Leng S, Davidge ST, Flores ER, Eisenstat DD, Leng R. p63, a key regulator of Ago2, links to the microRNA-144 cluster. Cell Death Dis. 2022 Apr.13(4):397. Pubmedid: 35459267. Pmcid: PMC9033807.
  • Gomes AP, Ilter D, Low V, Drapela S, Schild T, Mullarky E, Han J, Elia I, Broekaert D, Rosenzweig A, Nagiec M, Nunes JB, Schaffer BE, Mutvei AP, Asara JM, Cantley LC, Fendt SM, Blenis J. Altered propionate metabolism contributes to tumour progression and aggressiveness. Nat Metab. 2022 Apr.4(4):435-443. Pubmedid: 35361954. Pmcid: PMC9050834.
  • Ampomah PB, Cai B, Sukka SR, Gerlach BD, Yurdagul A, Wang X, Kuriakose G, Darville LNF, Sun Y, Sidoli S, Koomen JM, Tall AR, Tabas I. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat Metab. 2022 Apr.4(4):444-457. Pubmedid: 35361955. Pmcid: PMC9050866.
  • Mahajan S, Majumder A, Stewart PA, Chen YA, Adhikari E, Fang B, Yang Y, Lawrence H, Kinose F, Koomen JM, Haura EB. Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. Acs Chem Biol. 2022 Apr.17(4):776-784. Pubmedid: 35311290.
  • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
  • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
  • Wang Y, Binning JM, Pintilie GD, Chiu W, Amarasinghe GK, Leung DW, Su Z. Cryo-EM analysis of Ebola virus nucleocapsid-like assembly. STAR Protoc. 2022 Mar.3(1):101030. Pubmedid: 34977676. Pmcid: PMC8689349.
  • Andor N, Altrock PM, Jain N, Gomes AP. Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy. Cancer Res. 2022 Mar.82(5):741-748. Pubmedid: 34785577. Pmcid: PMC8898264.
  • Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. Author Correction: ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Mar.13(1):1717. Pubmedid: 35338160. Pmcid: PMC8956651.
  • Karim RM, Yang L, Chen L, Bikowitz MJ, Lu J, Grassie D, Shultz ZP, Lopchuk JM, Chen J, Schönbrunn E. Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain. J Med Chem. 2022 Mar.65(5):4182-4200. Pubmedid: 35191694.
  • Bok I, Angarita A, Douglass SM, Weeraratna AT, Karreth FA. A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities. JID Innov. 2022 Mar.2(2):100076. Pubmedid: 35146482. Pmcid: PMC8819036.
  • Napoli M, Wu SJ, Gore BL, Abbas H, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun. 2022 Feb.13(1):614. Pubmedid: 35105868. Pmcid: PMC8807845.
  • Yaghjyan L, Darville LNF, Cline J, Martinez YC, Rich S, Austin-Datta RJ, Koomen JM, Tworoger SS, Egan KM. Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women. Cancer Causes Control. 2022 Feb.33(2):279-291. Pubmedid: 34988766.
  • Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chem Biol. 2022 Feb.29(2):202-214.e7. Pubmedid: 34329582. Pmcid: PMC8782927.
  • Mecozzi N, Nenci A, Vera O, Bok I, Falzone A, DeNicola GM, Karreth FA. Genetic tools for the stable overexpression of circular RNAs. RNA Biol. 2022 Jan.19(1):353-363. Pubmedid: 35289721. Pmcid: PMC8928841.
  • Nakamura K, Reid BM, Chen A, Chen Z, Goode EL, Permuth JB, Teer JK, Tyrer J, Yu X, Kanetsky PA, Pharoah PD, Gayther SA, Sellers TA, Lawrenson K, Karreth FA. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer. Am J Hum Genet. 2022 Jan.109(1):116-135. Pubmedid: 34965383. Pmcid: PMC8764204.
  • Pandey G, Kuykendall AT, Reuther GW. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022 Jan.12(1):13. Pubmedid: 35082276. Pmcid: PMC8792018.
  • Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 Dec.127(23):4413-4420. Pubmedid: 34358340.
  • Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, Galvez-Reyes J, Kalekar RL, Mulugeta N, Kapner KS, Raghavan MS, Borah AA, Liu N, Väyrynen SA, Costa AD, Ng RWS, Wang J, Hill EK, Ragon DY, Brais LK, Jaeger AM, Spurr LF, Li YY, Cherniack AD, Booker MA, Cohen EF, Tolstorukov MY, Wakiro I, Rotem A, Johnson BE, McFarland JM, Sicinska ET, Jacks TE, Sullivan RJ, Shapiro GI, Clancy TE, Perez K, Rubinson DA, Ng K, Cleary JM, Crawford L, Manalis SR, Nowak JA, Wolpin BM, Hahn WC, Aguirre AJ, Shalek AK. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 Dec.184(25):6119-6137.e26. Pubmedid: 34890551. Pmcid: PMC8822455.
  • Mo Q, Wan L, Schell MJ, Jim H, Tworoger SS, Peng G. Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma. Cancers (Basel). 2021 Dec.13(24). Pubmedid: 34944787. Pmcid: PMC8699355.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Drapela S, Gomes AP. Metabolic requirements of the metastatic cascade. Curr Opin Syst Biol. 2021 Dec.28. Pubmedid: 34693082. Pmcid: PMC8535854.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
  • Westcott PMK, Sacks NJ, Schenkel JM, Ely ZA, Smith O, Hauck H, Jaeger AM, Zhang D, Backlund CM, Beytagh MC, Patten JJ, Elbashir R, Eng G, Irvine DJ, Yilmaz OH, Jacks T. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021 Oct.2(10):1071-1085. Pubmedid: 34738089. Pmcid: PMC8562866.
  • Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM, Hwang WL, Schenkel JM, Jaeger AM, Bronson RT, Westcott PMK, Hether TD, Divakar P, Reeves JW, Deshpande V, Delorey T, Phillips D, Yilmaz OH, Regev A, Jacks T. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021 Oct.39(10):1342-1360.e14. Pubmedid: 34358448. Pmcid: PMC8511341.
  • Liu CH, Rao Y, Gao D, Wan L, Zhang L. Editorial: Ubiquitin Code: From Cell Biology to Translational Medicine. Front Cell Dev Biol. 2021 Oct.9:791967. Pubmedid: 34778279. Pmcid: PMC8581446.
  • Lee K, Lockhart JH, Xie M, Chaudhary R, Slebos RJC, Flores ER, Chung CH, Tan AC. Deep Learning of Histopathology Images at the Single Cell Level. Front Artif Intell. 2021 Sep.4:754641. Pubmedid: 34568816. Pmcid: PMC8461055.
  • Burger ML, Cruz AM, Crossland GE, Gaglia G, Ritch CC, Blatt SE, Bhutkar A, Canner D, Kienka T, Tavana SZ, Barandiaran AL, Garmilla A, Schenkel JM, Hillman M, de Los Rios Kobara I, Li A, Jaeger AM, Hwang WL, Westcott PMK, Manos MP, Holovatska MM, Hodi FS, Regev A, Santagata S, Jacks T. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021 Sep.184(19):4996-5014.e26. Pubmedid: 34534464. Pmcid: PMC8522630.
  • Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021 Sep.35(9):2469-2481. Pubmedid: 34127794. Pmcid: PMC8764661.